TY - JOUR
T1 - Human β nerve growth factor obtained from a baculovirus expression system has potent in vitro and in vivo neurotrophic activity
AU - Barnett, Jim
AU - Baecker, Preston
AU - Routledge-Ward, Carol
AU - Bursztyn-Pettegrew, Hela
AU - Chow, Joan
AU - Nguyen, Binh
AU - Bach, Chinh
AU - Chan, Hardy
AU - Tuszynski, Mark H.
AU - Yoshida, Kazunari
AU - Rubalcava, Rafael
AU - Gage, Fred H.
N1 - Funding Information:
We are grateful to Dr. Eric Shooter for his helpful suggestions and reagents. We also thank Linda Fish, Mary Jane McRoberts, Carole Kurahara, D. Chen, and S. Forbes for their technical assistance. This work was conducted in part with funds from the NIA (AGO 0353A and AGO 5131), the Pew Foundation, and the Herbert and Margaret Hoover Jr,. Foundation.
PY - 1990/10
Y1 - 1990/10
N2 - A baculovirus expression vector, which contains the coding sequences for human prepro (β) nerve growth factor under control of the viral polyhedrin promoter, was constructed. Upon infection of insect cells with the recombinant virus, mature human β nerve growth factor (rhNGF) was released into the culture fluid. The mature rhNGF was biologically active since rat pheochromocytoma (PC12) and human neuroblastoma (SH-SY5Y) cells were induced to extend neurites upon treatment with this material. This activity was abolished by treating with antiserum prepared against mature mouse β NGF (mNGF). When compared with mNGF, rhNGF more rapidly elicited the differentiation response in both PC12 and SH-SY5Y cells. In an in vivo assay of cholinergic cell survival, rhNGF was nearly as potent as mNGF in protecting cholinergic neurons from degeneration following a fimbria-fornix lesion. These results show that the baculovirus expression system provides quantities of biologically potent human β NGF suitable for a comprehensive program of research to ascertain β NGF's potential as a therapeutic agent for the treatment of Alzheimer's disease.
AB - A baculovirus expression vector, which contains the coding sequences for human prepro (β) nerve growth factor under control of the viral polyhedrin promoter, was constructed. Upon infection of insect cells with the recombinant virus, mature human β nerve growth factor (rhNGF) was released into the culture fluid. The mature rhNGF was biologically active since rat pheochromocytoma (PC12) and human neuroblastoma (SH-SY5Y) cells were induced to extend neurites upon treatment with this material. This activity was abolished by treating with antiserum prepared against mature mouse β NGF (mNGF). When compared with mNGF, rhNGF more rapidly elicited the differentiation response in both PC12 and SH-SY5Y cells. In an in vivo assay of cholinergic cell survival, rhNGF was nearly as potent as mNGF in protecting cholinergic neurons from degeneration following a fimbria-fornix lesion. These results show that the baculovirus expression system provides quantities of biologically potent human β NGF suitable for a comprehensive program of research to ascertain β NGF's potential as a therapeutic agent for the treatment of Alzheimer's disease.
UR - http://www.scopus.com/inward/record.url?scp=0025130888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025130888&partnerID=8YFLogxK
U2 - 10.1016/0014-4886(90)90047-V
DO - 10.1016/0014-4886(90)90047-V
M3 - Article
C2 - 2209779
AN - SCOPUS:0025130888
SN - 0014-4886
VL - 110
SP - 11
EP - 24
JO - Experimental Neurology
JF - Experimental Neurology
IS - 1
ER -